Benefits of nasal saline treatment in acute rhinosinusitis: Systematic review and meta-analysis
Issued Date
2022-08-01
Resource Type
ISSN
20426976
eISSN
20426984
Scopus ID
2-s2.0-85122733247
Pubmed ID
34971301
Journal Title
International Forum of Allergy and Rhinology
Volume
12
Issue
8
Start Page
1006
End Page
1017
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Forum of Allergy and Rhinology Vol.12 No.8 (2022) , 1006-1017
Suggested Citation
Chitsuthipakorn W., Kanjanawasee D., Hoang M.P., Seresirikachorn K., Snidvongs K. Benefits of nasal saline treatment in acute rhinosinusitis: Systematic review and meta-analysis. International Forum of Allergy and Rhinology Vol.12 No.8 (2022) , 1006-1017. 1017. doi:10.1002/alr.22957 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85701
Title
Benefits of nasal saline treatment in acute rhinosinusitis: Systematic review and meta-analysis
Other Contributor(s)
Abstract
Background: Although nasal saline treatments are widely used in treating acute rhinosinusitis (ARS), the evidence in adult patients is inconclusive. Our objective was to assess the add-on benefits of saline treatment in adults with ARS. Methods: Literature searches were performed (updated May 9, 2021). Randomized, controlled trials studying the effects of nasal saline treatment in adults with ARS were included. Data were pooled for meta-analysis. Outcomes were composite symptoms score (CSS), disease-specific quality-of-life (DS-QoL) score, individual symptom score, endoscopy score, saccharin transit time, cure rate, days to resolution, and adverse events. Results: Eleven studies (718 patients) were included in our investigation. Nasal discharge was the only symptom improved (standardized mean difference [SMD], −0.36; 95% confidence interval [CI], −0.66 to −0.05]. Saline as an add-on treatment brought no benefit to CSS and DS-QoL score at both time-points (3-10 days and at the end of the study). Other outcomes also showed no benefits with use of saline, including endoscopy score, saccharin transit time, cure rate, days to resolution, and adverse events. Subgroup analyses showed improvement in viral ARS patients for CSS (SMD, −0.60; 95% CI, −1.12 to −0.08) and DS-QoL score (mean difference, −15.90; 95% CI, −31.78 to −0.02), and also in patients using high-volume saline (SMD, −0.42; 95% CI, −0.78 to −0.06). Conclusion: Nasal saline as an add-on treatment improved rhinorrhea. There was no improvement in CSS and DS-QoL, except among the subgroup of viral ARS patients using high-volume saline. There were no differences in adverse events between the saline and non-saline treatments.